Cardia Bioplastics (ASX:CNN) (OTCMKTS:CDRBY) Compostable Resin and Process Secures Patents in USA

Cardia Bioplastics Limited (ASX:CNN) (OTCMKTS:CDRBY) is pleased to announce that it has secured patent protection for its Cardia Compostable resin family of products from the United States Patent and Trademark Office. The U.S. patents 8,067,485 and 8,232,348 were granted for Cardia's unique and innovative compostable resin formulations and production processes.

Highlights:

- United States Patent and Trademark Office grants patents for Cardia Compostable resin and process
- Intellectual Property underpins commercially successful Cardia Compostable product range
- Cardia Bioplastics' technical differentiation endorsed with patents
- Cardia capitalises on growth of bioplastics in the North American market

To view the media release, please visit:
http://media.abnnewswire.net/media/en/docs/76672-ASX-CNN-784088.pdf' target=_blank>http://media.abnnewswire.net/media/en/docs/76672-ASX-CNN-784088.pdf' target=_blank>http://media.abnnewswire.net/media/en/docs/76672-ASX-CNN-784088.pdf

Richard Tegoni
Chairman
Cardia Bioplastics Limited


About Cardia Bioplastics Limited

Cardia Bioplastics Limited (ASX:CNN) develops, manufactures and markets its patented renewable resource-based materials and finished products derived from Cardia's proprietary technology for the global packaging and plastic products industries. The company holds a strong patent portfolio and its growth is fuelled by the global trend towards sustainable packaging. Established in Australia in 2002 as Biograde, the company Headquarters and Global Applications Development Centre is in Melbourne, Australia. The Product Development Centre and manufacturing plant for resins and finished goods is in Nanjing, China.

Cardia Bioplastics has offices in Australia, China, USA, Brazil and Malaysia, and a network of leading distributors across the Americas, Asia and Europe.


Related Companies

Cardia Bioplastics Limited